Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts
- PMID: 1314653
- DOI: 10.1021/bi00131a013
Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts
Abstract
A series of site-specifically plantinated, covalently closed circular M13 genomes (7250 bp) was constructed in order to evaluate the consequences of DNA template damage induced by the anticancer drug cis-diamminedichloroplatinum(II) (cis-DDP). Here are reported the synthesis and characterization of genomes containing the intrastrand cross-linked adducts cis-[Pt(NH3)2[d(ApG)-N7(1),-N7(2)]], cis-[Pt-(NH3)2[d(GpCpG)-N7(1),-N7(3)]], and trans-[Pt(NH3)2[d(CpGpCpG)-N3(1),-N7(4)]]. These constructs, as well as the previously reported M13 genome containing a site-specifically placed cis-[Pt(NH3)2[d-(GpG)-N7(1),-N7(2)]] adduct, were used to study replication in vitro. DNA synthesis was initiated from a position approximately 177 nucleotides 3' to the individual adducts, and was terminated either by the adducts or by the end of the template, located approximately 25 nucleotides on the 5' side of the adducts. Analysis of the products of these reactions by gel electrophoresis revealed that, on average, bypass of the cis-DDP adducts occurred approximately 10% of the time and that the cis-[Pt(NH3)2[d(GpG)-N7(1),-N7(2)]] intrastrand cross-link is the most inhibitory lesion. The cis-[Pt(NH3)2[(GpCpG)-N7(1),-N7(3)]] adduct allowed a higher frequency of such translesion synthesis (ca. 25%) for two of the polymerases studied, modified bacteriophage T7 polymerase and Escherichia coli DNA polymerase I (Klenow fragment). These enzymes have either low (Klenow) or no (T7) associated 3' to 5' exonuclease activity. Bacteriophage T4 DNA polymerase, which has a very active 3' to 5' exonuclease, was the most strongly inhibited by all three types of cis-DDP adducts, permitting only 2% translesion synthesis. This enzyme is therefore recommended for replication mapping studies to detect the location of cis-DDP-DNA adducts in a heterologous population. The major replicative enzyme of E. coli, the DNA polymerase III holoenzyme, allowed less than 10% adduct bypass. Postreplication restriction enzyme cleavage studies established that the templates upon which translesion synthesis was observed contained platinum adducts, ruling out the possibility that the observed products were due to a small amount of contamination with unplatinated DNA. The effects on in vitro replication of a recently characterized adduct of trans-DDP [Comess, K. M., Costello, C. E., & Lippard, S. J. (1990) Biochemistry 29, 2102-2110] were also evaluated. This adduct provided a poor block both to DNA polymerases and to restriction enzymes.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis-[Pt(NH3)2(d(GpG]], built into a specific site in a viral genome.Biochemistry. 1988 Jun 14;27(12):4357-67. doi: 10.1021/bi00412a024. Biochemistry. 1988. PMID: 3166983
-
RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II).Biochemistry. 1992 Feb 25;31(7):1904-8. doi: 10.1021/bi00122a002. Biochemistry. 1992. PMID: 1536834
-
Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.Biochemistry. 1990 Jun 19;29(24):5872-80. doi: 10.1021/bi00476a032. Biochemistry. 1990. PMID: 2383564
-
Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.Met Ions Biol Syst. 1996;33:105-41. Met Ions Biol Syst. 1996. PMID: 8742842 Review.
-
Cisplatin: synthesis, antitumour activity and mechanism of action.Pharm Weekbl Sci. 1985 Oct 25;7(5):173-80. doi: 10.1007/BF02307573. Pharm Weekbl Sci. 1985. PMID: 3906559 Review.
Cited by
-
Telomere loss in cells treated with cisplatin.Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4219-23. doi: 10.1073/pnas.95.8.4219. Proc Natl Acad Sci U S A. 1998. PMID: 9539717 Free PMC article.
-
DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene.Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5356-60. doi: 10.1073/pnas.92.12.5356. Proc Natl Acad Sci U S A. 1995. PMID: 7777511 Free PMC article.
-
Combination of Ru(ii) complexes and light: new frontiers in cancer therapy.Chem Sci. 2015 May 1;6(5):2660-2686. doi: 10.1039/c4sc03759f. Epub 2015 Jan 13. Chem Sci. 2015. PMID: 29308166 Free PMC article.
-
Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene.Nucleic Acids Res. 1994 Jul 11;22(13):2519-24. doi: 10.1093/nar/22.13.2519. Nucleic Acids Res. 1994. PMID: 8041613 Free PMC article.
-
Cisplatin in the era of PARP inhibitors and immunotherapy.Pharmacol Ther. 2024 Jun;258:108642. doi: 10.1016/j.pharmthera.2024.108642. Epub 2024 Apr 16. Pharmacol Ther. 2024. PMID: 38614254 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources